Condition: Friedreich Ataxia · Sponsor: Larimar Therapeutics, Inc.
An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of CTI-1601 enrolling adolescent and adult patients with FRDA who have participated in a prior clinical study of CTI-1601 as well as children (age 2 years and older), adolescents and adults with FRDA who have not participated in a prior clinical study of CTI-1601.
This description comes directly from the study's public registry record.
Larimar Therapeutics, Inc. · 844-511-9056 · info@larimartx.com
Always discuss trial participation with your own doctor first.
| University of California Los Angeles | Los Angeles, California, United States | Recruiting |
| Fixel Institute for Neurological Disease, University of Florida Health | Gainesville, Florida, United States | Active Not Recruiting |
| Morsani Center for Advanced Health Care, University of South Florida Health | Tampa, Florida, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| Uncommon Cures | Chevy Chase, Maryland, United States | Recruiting |
| Clinilabs Drug Development, Corp. | Eatontown, New Jersey, United States | Recruiting |
| Ohio State University United States | Columbus, Ohio, United States | Active Not Recruiting |
| Children's Hospital of the University of Pennsylvania (CHOP) | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06447025